Dr. Hamrah is investigating the efficiency of local adoptive transfer of plasmacytoid dendritic cells in improving allograft survival in ‘high-risk’ corneal transplantation.
This study will provide fundamental data on the role of pDCs in corneal transplantation for a future clinical trial and could lead to novel immune therapies for other corneal conditions and solid organ transplants.
From left, Eversight Business Development Director Caithlin Lopes, Pedram Hamrah, MD and co-investigator Fangfang Qui
Dr. Kumar is investigating the role of dual acting nanoformulations for the treatment of ocular bacterial infections.
Knowledge gained from this study could improve treatment for patients with ocular bacterial infections that often result in partial or complete vision loss despite current antibiotic and surgical interventions.
From left, Wayne State University's Linda Hazlett, PhD and Ashok Kumar, PhD, Eversight's Ebony Johnson and Wayne State University's Mark Juzych, MD.
Dr. Miller is investigating the understanding of pathoetiology of pathologic extracellular deposits in age-related macular degeneration by defining the mechanism and composition of retinal pigment epithelial (RPE) lipoprotein secretion.
Better understanding the fats involved in RPE lipoprotein particles will inform which pathways in the cell could be targeted therapeutically to prevent buildup of toxic retinal deposits that cause AMD.
From left, Eversight Partner Relations Director Ebony Johnson, Jason Miller, MD, PhD and Eversight Philanthropy Director of Foundations & Corporations Becky Harris.
Dr. Prasov is investigating the role of developing gene editing for corneal dystrophies.
An eventual gene therapy could prevent vision loss and reduce the need for corneal transplantation in patients with corneal dystrophy.
From left, Eversight Partner Relations Director Ebony Johnson, Lev Prasov, MD, PhD, Yan Zhang, PhD and Eversight Philanthropy Director of Foundations & Corporations Becky Harris.
Interested in receiving periodic news and updates from Eversight? We invite you to sign up to receive our emails.
